Patenting Biologics and Biosimilars in the United Kingdom (2026): What Life‑sciences Companies Need to Know

Biologics patents united kingdom decisions have rarely carried more commercial weight than they do in 2026, as the surge in RNA and vaccine filings pushes originators and biosimilar developers alike to sharpen their strategies. This decision guide is written for in‑house counsel, R&D and licensing leads, and biotech founders who must choose between building strong exclusionary patent portfolios or clearing a path to biosimilar market entry. It sets out the statutory basis for protecting biological inventions, the practical differences between prosecution at the UK Intellectual Property Office and the European Patent Office, concrete drafting rules for antibodies and mRNA constructs, a freedom‑to‑operate checklist, and enforcement tactics on both sides of the dispute.

The article ends with a clear decision framework, a side‑by‑side comparison and explicit “choose A when…” and “choose B when…” rules, so you leave with a position, not a hedge.

Can biologics be patented in the United Kingdom?

Yes. Biological inventions are patentable in the United Kingdom subject to the same core statutory tests that apply to any invention. The Patents Act 1977 requires that an invention be new, involve an inventive step, be capable of industrial application, and be disclosed clearly and completely enough to be performed by a person skilled in the art. Biologics patents united kingdom applications succeed or fail on precisely these criteria, with sufficiency and inventive step doing most of the heavy lifting in practice.

UK patent law is closely aligned with the European Patent Convention, because most UK patents in the life‑sciences space arrive via European Patent Office grant and national validation. The EPO’s approach to biotechnology, and the biotechnology provisions incorporated into the Implementing Regulations to the EPC, reflect the principles of Directive 98/44/EC on the legal protection of biotechnological inventions, which confirms that biological material isolated from its natural environment or produced by a technical process can be patentable even if it previously occurred in nature. That principle underpins the patentability of purified proteins, isolated nucleic acid sequences, expression vectors, cell lines and monoclonal antibodies.

In UK national law, the corresponding provisions are set out in Schedule A2 to the Patents Act 1977.

Certain exclusions apply. Methods of treatment of the human or animal body by surgery or therapy, and diagnostic methods practised on the body, are excluded, though products for use in such methods remain patentable. Processes for cloning human beings and uses of human embryos for industrial or commercial purposes are also excluded on ethical grounds. Understanding where the boundaries sit is central to any biologics patents united kingdom filing strategy.

Legal tests that matter (novelty, inventive step, sufficiency)

Three tests dominate. Novelty requires that the claimed subject matter not form part of the state of the art; for a purified biological the prior disclosure of the same molecule in the same form can be fatal. Inventive step asks whether the invention was obvious to the skilled person; predictable modifications to a known antibody or sequence are vulnerable. Sufficiency, the requirement under the Patents Act 1977 that the disclosure enable the skilled person to work the invention across the claim’s scope, is the most common battleground for biologics, where broad functional claims frequently outrun the enabling data. Getting these right at drafting stage is far cheaper than defending them later.

UK vs EPO practice, prosecution divergence to watch

Although the substantive tests overlap, prosecution diverges in ways that matter. The EPO applies its structured problem‑and‑solution approach to inventive step and follows detailed practice on sequence listings and functional features set out in the EPO Guidelines for Examination. UKIPO examination can take a more flexible view of inventive step reasoning, while both forums apply a strict approach to added matter. Post‑Brexit, the UK remains an EPC contracting state, so European patents still designate and validate in the UK, but UK national litigation and revocation proceed under UK law and precedent.

Note that the Unified Patent Court and unitary patent, which entered operation in participating EU states in 2023, do not extend to the UK; UK protection continues to be secured through UK national patents and the UK designation of European patents. Life‑sciences teams should plan biologics patents united kingdom strategy around both forums simultaneously.

Drafting biologics claims, types, examples and practical rules

Claim drafting for biologics is where value is created or destroyed. Unlike small‑molecule patents, where a single structural formula can define the compound precisely, biologics require a layered claim strategy that combines structure, function, process and product characterisation. A robust application typically deploys several claim formats in parallel so that if one falls, others survive.

• Product and composition claims. Define the biological entity itself, the protein, antibody, vector or nucleic acid, by sequence, structural features, or defined variant ranges, and separately claim pharmaceutical compositions incorporating it.
• Use and medical‑use claims. Claim the product for use in treating a specified condition; second‑medical‑use claims can extend protection to new indications during lifecycle management.
• Process claims. Protect the manufacturing route, the expression system, purification steps and formulation process, which is particularly powerful against biosimilars that struggle to replicate the exact process.
• Product‑by‑process claims. Define the product by the process used to make it, useful where the product cannot be adequately defined by structure alone. Note that in the UK and at the EPO such claims still require the product itself to be novel and inventive.
• Deposit claims. Where a biological material cannot be described in words sufficiently for the skilled person to reproduce it, a deposit under the Budapest Treaty supports sufficiency.

For antibodies, cell lines, vectors and mRNA constructs there are specific drafting rules. Sequence disclosure must be complete and consistent with the claims, and functional limitations must be supported by data across the claimed scope. The single most important discipline is to align claim breadth with the enabling disclosure, a point the EPO Guidelines return to repeatedly for biologics. When drafting biologics patents united kingdom applications, build in fallback positions from the outset so that examiners and opponents cannot collapse the entire claim set with one objection.

Antibody & epitope claims, practical language and pitfalls

Antibody patents UK practice has tightened considerably. Broad functional antibody claims, defining an antibody solely by its target antigen or by a desired binding property, are increasingly difficult to sustain unless the specification demonstrates that the skilled person can obtain antibodies across the claimed range without undue burden. The safer route is to define antibodies by their complementarity‑determining regions (CDR sequences), by reference to the epitope bound, or by a combination of structural and functional features supported by worked examples. Common pitfalls include claiming “an antibody that binds antigen X” with only one exemplified antibody, failing to define numbering conventions for CDRs, and omitting affinity or neutralisation data that would support functional limitations.

As a practical illustration, an application claiming a therapeutic antibody by target alone may need to be narrowed during EPO prosecution to a defined CDR set plus a functional neutralisation limitation, because the original breadth is unsupported. Draft antibody claims with structure‑plus‑function layering and multiple exemplified embodiments to preserve scope.

mRNA and vaccine constructs, sequence disclosure and functional claim drafting

Recent filing growth is concentrated in mRNA vaccine patents UK and related RNA constructs, delivery systems and modified nucleotides. Drafting here demands complete and accurate sequence disclosure, careful handling of codon‑optimised variants, and functional claims tied to demonstrated expression or immunogenicity. Claims to lipid nanoparticle delivery formulations, chemically modified nucleosides, and untranslated region designs each raise distinct enablement questions. Where a claim covers a family of sequence variants, the specification should exemplify enough of that family, and describe the design principles, to satisfy sufficiency across the range.

For mRNA vaccine patents UK filings, functional claim language (“an mRNA encoding an antigen that elicits a protective immune response”) must be underpinned by data, or examiners and opponents will attack it as speculative.

Claim breadth vs enablement, examples and red‑flag claim language

The recurring failure mode in biologics prosecution is a claim whose breadth outruns the data. Red‑flag language includes open‑ended functional definitions (“any variant retaining activity”), unbounded percentage identity ranges without exemplification, and claims to whole classes of molecules supported by a single example. The remedy is disciplined layering: a broad functional claim at the top, narrower structurally defined claims beneath, and specific exemplified embodiments at the base, each capable of standing alone. This structure protects biologics patents united kingdom positions during both examination and post‑grant opposition, because it forces any challenger to defeat each tier separately.

Freedom‑to‑operate and clearance for biosimilars entering the UK

For a biosimilar entrant, freedom‑to‑operate biologics UK analysis is the foundation of any launch plan. The task is to identify every patent and supplementary protection certificate that could read on the proposed product and its manufacture, assess validity and scope, and design a clearance route that either avoids infringement, defeats the blocking rights, or secures a licence. Because biologics are protected by dense thickets of product, formulation, process and second‑medical‑use rights, a superficial search is not enough.

Regulatory approval and patent clearance run on separate tracks. The European Medicines Agency sets out the scientific comparability framework that informs biosimilar development in the EU, and the Medicines and Healthcare products Regulatory Agency administers UK marketing authorisations post‑Brexit. Obtaining a UK marketing authorisation does not clear patent rights, a biosimilar can be approved yet still infringe a subsisting patent or SPC. Data and market exclusivity periods attaching to the reference product must also be mapped, as they can delay reliance on the originator’s dossier independently of patent term.

Quick FTO checklist (priority actions)

1. Identify the reference product and compile its full UK/EP patent and SPC landscape, including divisionals and pending applications.
2. Classify each right by type: product, formulation, process, medical use.
3. Assess subsistence and expiry, including any SPC term and paediatric extension.
4. Map your candidate product and process against each claim to test infringement.
5. Evaluate validity of blocking rights, sufficiency, novelty and inventive step vulnerabilities.
6. Decide the route: design‑around, invalidity challenge, clearing‑the‑way declaration, or licence.
7. Diarise expiry dates and monitor pending EP applications for grant.

Mapping claims to biosimilar differences (glycosylation, cell‑line, formulation)

Biosimilars are highly similar, not identical, and those differences are the entrant’s clearance opportunity. Glycosylation profiles, host cell‑line choice, purification process and final formulation can each take a product outside the scope of narrowly drafted claims. The clearance analysis should gather comparative analytical data early and test whether the biosimilar falls outside product claims defined by specific structural features, or outside process claims defined by particular manufacturing steps. Where an originator’s claims are broad and functionally defined, the entrant should assess whether they are vulnerable on sufficiency, since a claim broad enough to catch the biosimilar may be broad enough to be invalid.

This dual analysis, non‑infringement and invalidity together, is the core of biologics patents united kingdom clearance strategy for entrants.

Protection toolbox: SPCs, regulatory exclusivities and commercial remedies

Patents alone rarely maximise the commercial life of a biologic. A layered protection toolbox combines patent term with supplementary protection certificates and non‑patent exclusivities to extend and defend exclusivity against biosimilar entry.

SPC timing & application practicalities

Supplementary protection certificates compensate for the patent term lost to regulatory approval and can extend protection for a medicinal product for a maximum of five years beyond patent expiry. Under the UK Government’s SPC guidance, an SPC is available where the product is protected by a basic patent in force and a valid UK marketing authorisation exists. Timing is strict: the application must generally be filed within six months of the grant of the marketing authorisation, or within six months of grant of the patent where the patent is granted after the authorisation.

For biologics, careful attention is needed to how the active ingredient is defined in both the patent and the authorisation, since the product covered by the SPC must be identified consistently. File early, confirm the basic patent covers the product as authorised, and align the SPC strategy with the planned commercial launch and expected biosimilar entry date. A paediatric extension can add a further six months where the relevant conditions are met.

Non‑patent exclusivities and enforcement levers

Beyond patents and SPCs, regulatory exclusivities provide an independent layer. Data and market exclusivity periods attaching to the reference product’s dossier can prevent a biosimilar relying on that data or entering the market for a defined period, regardless of patent status. Orphan designation can confer additional market exclusivity for qualifying products. Lifecycle filings, new formulations, dosing regimens and indications, generate fresh patent rights that can extend effective protection. Together these levers, alongside the enforcement remedies available under the Patents Act 1977, form the practical arsenal for defending biologics patents united kingdom value against biosimilar competition.

Enforcement and dispute options in the UK and at the EPO

Enforcement runs on two tracks that must be managed together: opposition and appeal at the EPO, and litigation before the UK courts. Originators use these to preserve exclusivity; entrants use them to clear the way. The Patents Act 1977 provides the UK remedies, injunctions, damages or an account of profits, and delivery up, while the EPO provides a centralised route to attack or defend the validity of a European patent before national rights crystallise.

EPO oppositions & appeals, tactical timelines and evidence strategies

An opposition may be filed at the EPO within nine months of publication of the mention of grant of a European patent, and can result in the patent being revoked, maintained as granted, or maintained in amended form, with effect across all designated states including the UK. This makes the opposition window a critical juncture for biosimilar entrants, since a successful opposition can remove a blocking right before it is enforced nationally. Evidence strategy matters: comparative experimental data, prior‑art documents establishing lack of novelty or obviousness, and technical expert declarations addressing sufficiency are the standard tools. The EPO Boards of Appeal case law provides the framework for assessing how breadth, functional claiming and sufficiency arguments are likely to be received.

Because appeals can take years, parties must plan for a multi‑year timeline and preserve their strongest arguments for the appeal stage.

UK litigation posture, interim relief, technical evidence and claim construction

UK patent litigation turns heavily on claim construction and technical evidence. The Supreme Court in Actavis UK Ltd v Eli Lilly & Co [2017] UKSC 48 reshaped UK infringement analysis by recognising a doctrine of equivalents, so that a product may infringe even if it falls outside the normal (literal) interpretation of a claim where it achieves substantially the same result in substantially the same way. For biologics, this expands the risk landscape for entrants relying on minor structural or process differences, and correspondingly strengthens originators’ hand where equivalents can be established.

Interim injunctions are available but demand a strong case and prompt action; biosimilar entrants frequently seek to “clear the way” by launching invalidity or non‑infringement declaration proceedings before market entry to reduce the risk of an injunction. Technical evidence, analytical characterisation, process comparisons and expert testimony, is decisive in biologics patents united kingdom disputes.

Decision framework, choose a route (originator vs biosimilar entrant)

The central strategic choice is whether to invest in a patent‑first exclusionary strategy as an originator, or a clearance‑first market‑entry strategy as a biosimilar developer. The table below sets the two routes side by side; the decision rules that follow tell you which to choose.

Choose the originator / patent‑first route when:

• You have robust enabling data across the claimed sequences and processes, and commercial margins justify the legal investment.
• Your business model relies on exclusivity and you can secure an SPC or regulatory exclusivity to extend term.
• You can support broad functional claims with exemplified embodiments and resource EPO/UK prosecution and opposition defence.

Choose the biosimilar entrant / clearance‑first route when:

• You need rapid market entry following loss of exclusivity, or where SPCs are absent or near expiry.
• There are clear technical differences, manufacturing, glycosylation, formulation, that take your product outside the claim scope.
• The cost of prolonged litigation exceeds the expected return, or a licensing or settlement route is available and commercially attractive.

Practical next steps checklist for counsel (0–90 days)

Whichever route you take, the first ninety days set the trajectory. Move on the following in parallel:

1. Days 0–30. Commission a full patent and SPC landscape for the target biologic; classify rights by type and expiry; identify pending EP applications to monitor.
2. Days 0–30. For originators, audit enabling data against intended claim breadth; for entrants, initiate comparative analytical characterisation.
3. Days 30–60. Draft or review claim sets with layered fallbacks; confirm sequence listings and deposit requirements; set SPC watch and application timelines.
4. Days 30–60. Complete the freedom‑to‑operate assessment and decide the clearance route, design‑around, invalidity, or licence.
5. Days 60–90. Prepare enforcement or opposition readiness: preserve evidence, brief technical experts, and diarise the nine‑month EPO opposition window for relevant grants.
6. Days 60–90. Align the IP strategy with the regulatory timetable and planned launch date; escalate any grey legal areas to specialist counsel.

Conclusion

Biologics patents united kingdom strategy in 2026 rewards decisiveness. Originators who back broad claims with genuine enabling data, secure SPCs and prepare for EPO opposition defence will hold durable exclusivity; entrants who run rigorous freedom‑to‑operate analysis, exploit real technical differences and challenge over‑broad claims on sufficiency will enter faster and at lower risk. Choose the patent‑first route when your data and margins support it, and the clearance‑first route when speed and technical workarounds favour early entry. Because several areas, claim breadth, equivalents and SPC scope, remain fact‑sensitive, engage specialist patent counsel before acting on any decision.

Sources

1. Patents Act 1977 (legislation.gov.uk)
2. European Patent Convention (EPC), official text (EPO)
3. EPO Guidelines for Examination (Biotechnology section)
4. Directive 98/44/EC on the legal protection of biotechnological inventions (EUR-Lex)
5. UK Government: Supplementary protection certificates (SPCs) guidance (gov.uk)
6. European Medicines Agency (EMA), Biosimilar medicines overview
7. Actavis UK Ltd v Eli Lilly & Co [2017] UKSC 48 (BAILII)
8. EPO Case Law of the Boards of Appeal
9. Medicines and Healthcare products Regulatory Agency (MHRA)